BRIEF published on 10/30/2026 at 06:35, 8 days 2 hours ago Nicox: Financial report for the first half of 2026 Financial Results Treasury Ophthalmology NCX 470 Future Strategy
BRIEF published on 09/16/2026 at 07:35, 1 month 21 days ago Nicox: NCX 470 data presentation at the 2026 AAOpt Congress Phase 3 Ophthalmology Nicox NCX 470 AAOpt Congress
PRESS RELEASE published on 09/16/2026 at 07:30, 1 month 21 days ago Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026 Nicox presents key data on NCX 470 at AAOpt Annual Meeting 2026, focusing on glaucoma management. Details on clinical trials and future conference participation Clinical Trials Ophthalmology Nicox NCX 470 AAOpt
BRIEF published on 09/11/2026 at 07:35, 1 month 26 days ago Nicox's NCX 470 NDA Accepted for Review in China Ophthalmology NCX 470 Ocumension Therapeutics China Market NDA Review
PRESS RELEASE published on 09/11/2026 at 07:30, 1 month 26 days ago Nicox Announces NCX 470 NDA in China Accepted for Review Nicox announces acceptance of NCX 470 NDA in China by NMPA for review. Regulatory decision expected 12-18 months post-submission. Details on Ocumension and NCX 470 milestones China Nicox NCX 470 Regulatory Decision NMPA
BRIEF published on 09/02/2026 at 07:35, 2 months 5 days ago Nicox Extends Its Cash Flow Horizon Thanks to NCX 470 Ophthalmology NDA Nicox NCX 470 Cash Flow Horizon
BRIEF published on 09/02/2026 at 07:35, 2 months 5 days ago Nicox Announces Financial Stability Extension Financial Update Ophthalmology Nicox NCX 470 Cash Runway
PRESS RELEASE published on 09/02/2026 at 07:30, 2 months 5 days ago Nicox Announces Extension of Cash Runway Nicox extends cash runway with estimated €8.4 million as of 31 August 2026, supporting operations beyond Q1 2028. NCX 470 U.S. NDA approval milestone could fund operations into 2029 Financial Update Ophthalmology Nicox NCX 470 Cash Runway
BRIEF published on 08/27/2026 at 07:35, 2 months 11 days ago Nicox: PDUFA date set for the NCX 470 in April 2027 FDA Glaucoma Nicox NCX 470 PDUFA
PRESS RELEASE published on 08/27/2026 at 07:30, 2 months 11 days ago Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma Nicox announces April 2027 PDUFA date for NCX 470 in Glaucoma. Positive results from Phase 3 trials pave the way for potential FDA approval and commercial launch in H2 2027 FDA Approval Glaucoma Nicox NCX 470 PDUFA Date
Published on 11/06/2026 at 22:15, 10 hours 28 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 19 hours 43 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 20 hours 13 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 20 hours 13 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 12 hours 28 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 13 hours 28 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 13 hours 43 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 14 hours 11 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 14 hours 43 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 14 hours 43 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 14 hours 49 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 15 hours 8 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
